Sellas Life Sciences to present preclinical SLS009 pancreatic cancer data at AACR meeting in September 2026

PUBT · 1d ago
Sellas Life Sciences to present preclinical SLS009 pancreatic cancer data at AACR meeting in September 2026
  • Sellas announced three preclinical studies of SLS009 (tambiciclib), a CDK9 inhibitor, in pancreatic ductal adenocarcinoma models.
  • Results will be presented in the future at the AACR Conference on Pancreatic Cancer on Sept. 25-28, 2026, in San Diego.
  • Posters focus on potential anti-tumor activity in patient-derived KRAS-mutant organoids, including MYC-linked vulnerabilities and combination strategies.
  • Work supports a broader development rationale for SLS009 in solid tumors, signaling continued investment in expansion beyond current late-stage programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020830PRIMZONEFULLFEED9819975) on September 02, 2026, and is solely responsible for the information contained therein.